Dylan Essner explains how Epic, an electronic medical record, can be used by nurses and oncology providers who are treating patients with chimeric antigen receptor T-cell therapy.
Dylan Essner, an Epic Beacon Analyst at Washington University in St. Louis, explains how Epic, an electronic medical record (EMR), can be used by nurses and oncology providers who are treating patients with chimeric antigen receptor (CAR) T-cell therapy.
Essner describes the CAR T cell section of the Epic system and how the documentation tools for the cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and immune-effector cell-associated encephalopathy (ICE) flowsheets. These 3 are all together in a flowsheet template for providers and nurses to document their patients.
ICANS and ICE have a formula built into the flowsheets, according to Essner, which allows the system to auto-populate the grade and score of the document. Medical professionals only need to input the different data points for each flowsheet; the grade for the patient will be calculated automatically. For patients with CRS, there is an informational chart to grade with. After the information has been added to a flowsheet, smart links will pull the data into the progress notes of the patient, which will make documentation easier for nurses and physicians.
<< View more resources and information regarding CAR T-cell therapy
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More
Landgren on MRD as an End Point for Multiple Myeloma Trials
May 1st 2024C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and the implications of this vote in the myeloma research field.
Read More